Summary
Global Markets Direct’s, ‘Celgene Corporation - Product Pipeline Review - 2016’, provides an overview of the Celgene Corporation’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Celgene Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Celgene Corporation
- The report provides overview of Celgene Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Celgene Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Celgene Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Celgene Corporation’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Celgene Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Celgene Corporation’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Celgene Corporation Snapshot 6
Celgene Corporation Overview 6
Key Information 6
Key Facts 6
Celgene Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
Celgene Corporation - Pipeline Review 15
Pipeline Products by Stage of Development 15
Pipeline Products - Monotherapy 16
Pipeline Products - Partnered Products 17
Pipeline Products - Out-Licensed Products 20
Celgene Corporation - Pipeline Products Glance 22
Celgene Corporation - Late Stage Pipeline Products 22
Celgene Corporation - Clinical Stage Pipeline Products 24
Celgene Corporation - Early Stage Pipeline Products 26
Celgene Corporation - Drug Profiles 28
apremilast 28
lenalidomide 31
azacitidine 36
CC-90007 40
mongersen 43
paclitaxel albumin bound 44
pomalidomide 48
romidepsin 53
amrubicin hydrochloride 56
CC-11050 58
CC-220 59
GI-6207 61
GI-6301 63
PDA-002 64
spebrutinib besylate 65
Stem Cell Therapy for Hematological Malignancies, Non-Malignant Disorders and Hypoxic-ischemic Encephalopathy 67
CC-122 68
CC-223 70
PNK-007 71
CC-115 72
CC-90001 73
CC-90002 74
CC-90003 75
CC-90005 76
Cellular Immunotherapy to Target GD2 for Neuroblastoma 77
CTP-730 78
pinometostat 79
AVL-181 81
AVL-192 82
CC-0730671 83
CC-2142 84
CC-509 85
CC-539 86
Monoclonal Antibody 1 for Inflammation 87
Monoclonal Antibody 2 for Inflammation 88
Small Molecules for Undisclosed Indication 89
Small Molecules to Agonize ROR gamma for Breast Cancer 90
Antibody for Oncology 92
Antibody for Undisclosed Indication 93
CC-0739623 94
CC-2141 95
CC-90006 96
CC-90008 97
CC-90009 98
CC-90010 99
CC-90011 100
CSC-1 101
Drug for Hematological Disorders and Oncology 102
Drug to Inhibit Kinase for Inflammation 103
Drugs for Hematology and Oncology 104
Monoclonal Antibody Conjugate to Inhibit Protein S100-A9 for MDS 105
Small Molecule to Inhibit Brutons Tyrosine Kinase for Inflammation 106
Small Molecules for Inflammation 107
Small Molecules for Inflammation and Cancer 108
Small Molecules for Malaria 109
Celgene Corporation - Pipeline Analysis 110
Celgene Corporation - Pipeline Products by Target 110
Celgene Corporation - Pipeline Products by Route of Administration 112
Celgene Corporation - Pipeline Products by Molecule Type 113
Celgene Corporation - Pipeline Products by Mechanism of Action 114
Celgene Corporation - Recent Pipeline Updates 116
Celgene Corporation - Dormant Projects 157
Celgene Corporation - Discontinued Pipeline Products 160
Discontinued Pipeline Product Profiles 160
Celgene Corporation - Company Statement 161
Celgene Corporation - Locations And Subsidiaries 162
Head Office 162
Other Locations & Subsidiaries 162
Appendix 168
Methodology 168
Coverage 168
Secondary Research 168
Primary Research 168
Expert Panel Validation 168
Contact Us 168
Disclaimer 169
List of Tables
Celgene Corporation, Key Information 10
Celgene Corporation, Key Facts 10
Celgene Corporation - Pipeline by Indication, 2016 12
Celgene Corporation - Pipeline by Stage of Development, 2016 19
Celgene Corporation - Monotherapy Products in Pipeline, 2016 20
Celgene Corporation - Partnered Products in Pipeline, 2016 21
Celgene Corporation - Partnered Products/ Combination Treatment Modalities, 2016 22
Celgene Corporation - Out-Licensed Products in Pipeline, 2016 24
Celgene Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016 25
Celgene Corporation - Pre-Registration, 2016 26
Celgene Corporation - Phase III, 2016 27
Celgene Corporation - Phase II, 2016 28
Celgene Corporation - Phase I, 2016 29
Celgene Corporation - Preclinical, 2016 30
Celgene Corporation - Discovery, 2016 31
Celgene Corporation - Pipeline by Target, 2016 114
Celgene Corporation - Pipeline by Route of Administration, 2016 116
Celgene Corporation - Pipeline by Molecule Type, 2016 117
Celgene Corporation - Pipeline Products by Mechanism of Action, 2016 118
Celgene Corporation - Recent Pipeline Updates, 2016 120
Celgene Corporation - Dormant Developmental Projects,2016 161
Celgene Corporation - Discontinued Pipeline Products, 2016 164
Celgene Corporation, Other Locations 166
Celgene Corporation, Subsidiaries 166
List of Figures
Celgene Corporation - Pipeline by Top 10 Indication, 2016 12
Celgene Corporation - Pipeline by Stage of Development, 2016 19
Celgene Corporation - Monotherapy Products in Pipeline, 2016 20
Celgene Corporation - Partnered Products in Pipeline, 2016 21
Celgene Corporation - Out-Licensed Products in Pipeline, 2016 24
Celgene Corporation - Pipeline by Top 10 Target, 2016 114
Celgene Corporation - Pipeline by Route of Administration, 2016 116
Celgene Corporation - Pipeline by Molecule Type, 2016 117
Celgene Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016 118
